Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with relapsed or refractory plasmablastic lymphoma (PBL), confirmed through a tissue or cell sample test
• People who have at least one measurable area of disease — either a lymph node lesion of 1.5 cm or larger, or a lesion in another part of the body of 1.0 cm or larger
• People who have already received at least one previous treatment, including at least one round of chemotherapy or radiation
• People aged 18 years or older
• People who are generally able to carry out basic daily activities (a doctor will assess this using a standard scale)
• People whose blood count results meet certain minimum levels for red blood cells, white blood cells, and platelets (the trial site can confirm the specific numbers)
• People whose liver function test results are within an acceptable range (confirm with trial site)
• People whose kidneys are functioning at a sufficient level (confirm with trial site)
• People living with HIV who are on effective treatment and have had an undetectable viral load within the last 6 months
• People with a history of hepatitis B who are on suppressive therapy and have an undetectable viral load
• People with a history of hepatitis C who have been treated and cured, or who are currently being treated and have an undetectable viral load
• People who have lymphoma affecting the central nervous system (brain/spinal cord), provided they have no active symptoms at the time of joining, and the treating doctor determines that immediate treatment for that area is not needed during the first cycle of the trial
• People who have already had an autologous stem cell transplant (using their own cells), or who have been assessed as not being a suitable candidate for one
• People who have or have had another type of cancer, as long as that cancer or its treatment is not expected to interfere with this trial's results
• People with a history of heart disease or previous treatment with heart-affecting therapies, provided a doctor assesses their heart function as Class II or better on a standard scale
• People who are willing and able to use effective contraception during treatment and for a period after the last dose (specific timeframes differ depending on whether the person can become pregnant or can father a child — confirm details with the trial site)
• People who are able to understand the study and are willing to sign a consent form (a legally authorised representative may do this on their behalf)
• People who have not received a live virus vaccine for at least 4 weeks before starting treatment

Who may not be able to join:

• People who have not yet recovered from side effects of previous cancer treatments, where those side effects are still at a significant level (with the exception of hair loss or nerve-related symptoms)
• People who are currently taking part in another clinical trial involving an experimental treatment
• People who have had a serious allergic reaction to a drug that is chemically or biologically similar to the trial drug, teclistamab
• People with other serious, uncontrolled illnesses or conditions that would make participation in the trial unsafe
• People who are pregnant, as the trial drug may be harmful to an unborn baby
• People who are currently breastfeeding
• People who need supplemental oxygen to breathe adequately
• People who are taking steroid (corticosteroid) medications for reasons other than managing lymphoma symptoms — though inhaled steroids, certain steroids for low blood pressure, and steroids for adrenal insufficiency are permitted (confirm with trial site)
• People who have previously been treated with a therapy that targets a protein called BCMA
• People who have received a T-cell engager therapy (such as a bispecific antibody or CAR-T cell therapy) within the last 6 months

Important: Always verify eligibility with the trial site directly before applying.